ACADIA Pharmaceuticals Inc. (ACAD)

21.41
1.60 7.90
NASDAQ : Health Technology
Prev Close 19.85
Open 20.09
Day Low/High 20.01 / 21.85
52 Wk Low/High 12.77 / 41.20
Volume 5.24M
Avg Volume 3.01M
Exchange NASDAQ
Shares Outstanding 125.01M
Market Cap 2.52B
EPS -2.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
RM LAW Announces Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.

RM LAW Announces Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.

BERWYN, Pa., July 26, 2018 /PRNewswire/ --  RM LAW, P.

Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against ACADIA Pharmaceuticals Inc. - ACAD

Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against ACADIA Pharmaceuticals Inc. - ACAD

RADNOR, Pa., July 26, 2018 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors that a securities fraud class action lawsuit has been filed against ACADIA Pharmaceuticals Inc.

Federman & Sherwood Announces Filing Of Securities Class Action Lawsuit Against Acadia Pharmaceuticals, Inc.

Federman & Sherwood Announces Filing Of Securities Class Action Lawsuit Against Acadia Pharmaceuticals, Inc.

Federman & Sherwood announces that on July 19, 2018, a class action lawsuit was filed in the United States District Court for the Southern District of California against Acadia Pharmaceuticals, Inc.

New Securities Class Action Filed Against ACADIA Pharmaceuticals, Inc. (ACAD); Block & Leviton Encourages ACADIA Investors To Contact The Firm

New Securities Class Action Filed Against ACADIA Pharmaceuticals, Inc. (ACAD); Block & Leviton Encourages ACADIA Investors To Contact The Firm

BOSTON, July 24, 2018 /PRNewswire/ -- Block & Leviton LLP ( www.blockesq.

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against ACADIA Pharmaceuticals Inc. (ACAD) And Lead Plaintiff Deadline - September 17, 2018

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against ACADIA Pharmaceuticals Inc. (ACAD) And Lead Plaintiff Deadline - September 17, 2018

NEW YORK, July 24, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ACADIA Pharmaceuticals Inc.

Austin D. Kim, Executive Vice President, General Counsel And Secretary (Photo: Business Wire)

Austin D. Kim, Executive Vice President, General Counsel And Secretary (Photo: Business Wire)

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that Austin D.

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of ACADIA Pharmaceuticals Inc. (ACAD)

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of ACADIA Pharmaceuticals Inc. (ACAD)

NEW YORK, July 19, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals, Inc. (ACAD) Investigated By Block & Leviton LLP For Violations Of Federal Securities Laws

ACADIA Pharmaceuticals, Inc. (ACAD) Investigated By Block & Leviton LLP For Violations Of Federal Securities Laws

BOSTON, July 18, 2018 /PRNewswire/ -- Block & Leviton LLP ( www.blockesq.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against ACADIA Pharmaceuticals Inc. - ACAD

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against ACADIA Pharmaceuticals Inc. - ACAD

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of ACADIA Pharmaceuticals Inc.

Hagens Berman Alerts Investors In ACADIA Pharmaceuticals Inc. (ACAD) To The Firm's Investigation Of Possible Disclosure Violations

Hagens Berman Alerts Investors In ACADIA Pharmaceuticals Inc. (ACAD) To The Firm's Investigation Of Possible Disclosure Violations

SAN FRANCISCO, July 11, 2018 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in ACADIA Pharmaceuticals Inc.

August 24th Options Now Available For Acadia Pharmaceuticals (ACAD)

August 24th Options Now Available For Acadia Pharmaceuticals (ACAD)

Investors in Acadia Pharmaceuticals Inc saw new options begin trading today, for the August 24th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new August 24th contracts and identified one put and one call contract of particular interest.

NUPLAZID® (pimavanserin) Bottle (Photo: Business Wire)

NUPLAZID® (pimavanserin) Bottle (Photo: Business Wire)

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced FDA approval of a new capsule dose formulation and a new tablet strength of NUPLAZID (pimavanserin) to help in the treatment of patients living with hallucinations and delusions associated with...

ACADIA Pharmaceuticals To Present At The JMP Securities Life Sciences Conference On June 20, 2018

ACADIA Pharmaceuticals To Present At The JMP Securities Life Sciences Conference On June 20, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

ACADIA Pharmaceuticals To Present At The Goldman Sachs 39th Annual Global Healthcare Conference On June 13, 2018

ACADIA Pharmaceuticals To Present At The Goldman Sachs 39th Annual Global Healthcare Conference On June 13, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

3 Biotech Best Bets From the 'Stock Picker of the Year'

3 Biotech Best Bets From the 'Stock Picker of the Year'

In 2017, McCamant's model portfolio rose 65%, while his trader's portfolio rose 98%.

First Week Of July 20th Options Trading For Acadia Pharmaceuticals (ACAD)

Investors in Acadia Pharmaceuticals Inc saw new options begin trading this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new July 20th contracts and identified one put and one call contract of particular interest.

ACADIA Pharmaceuticals To Present At The Bank Of America Merrill Lynch Health Care Conference 2018

ACADIA Pharmaceuticals To Present At The Bank Of America Merrill Lynch Health Care Conference 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

ACADIA Pharmaceuticals Reports First Quarter 2018 Financial Results

ACADIA Pharmaceuticals Reports First Quarter 2018 Financial Results

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its financial...

Elena Ridloff, CFA, Senior Vice President, Investor Relations (Photo: Business Wire)

Elena Ridloff, CFA, Senior Vice President, Investor Relations (Photo: Business Wire)

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that Elena Ridloff,...

ACADIA Pharmaceuticals To Announce First Quarter 2018 Financial Results On May 4, 2018

ACADIA Pharmaceuticals To Announce First Quarter 2018 Financial Results On May 4, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its...

ACADIA Pharmaceuticals Announces Presentation Of Clinical Experience Data For NUPLAZID (Pimavanserin) At 2018 American Academy Of Neurology (AAN) Annual Meeting

ACADIA Pharmaceuticals Announces Presentation Of Clinical Experience Data For NUPLAZID (Pimavanserin) At 2018 American Academy Of Neurology (AAN) Annual Meeting

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced poster presentations...

ACADIA Pharmaceuticals Issues Statement Reaffirming Benefit/Risk Profile Of NUPLAZID

ACADIA Pharmaceuticals Issues Statement Reaffirming Benefit/Risk Profile Of NUPLAZID

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today issued the following statement: NUPLAZID ® (pimavanserin) is the only medicine approved in the United States to treat hallucinations and delusions associated with Parkinson's disease psychosis.

June 8th Options Now Available For Acadia Pharmaceuticals (ACAD)

Investors in Acadia Pharmaceuticals Inc saw new options become available today, for the June 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new June 8th contracts and identified the following call contract of particular interest.

PMDAlliance And ACADIA Pharmaceuticals Survey Reveals Serious Quality-of-Life Impact Of Non-Movement Symptoms Of Parkinson's Disease

PMDAlliance And ACADIA Pharmaceuticals Survey Reveals Serious Quality-of-Life Impact Of Non-Movement Symptoms Of Parkinson's Disease

As part of Parkinson's Disease Awareness Month, the Parkinson & Movement Disorder Alliance (PMDAlliance) and ACADIA Pharmaceuticals Inc.

Lennar, LG Homes, GrubHub, Sprint: 'Mad Money' Lightning Round

Lennar, LG Homes, GrubHub, Sprint: 'Mad Money' Lightning Round

Jim Cramer looks at Lennar, LG Homes, GrubHub, Sprint, Acadia Pharmaceuticals, Pilgrim's Pride, Opko Health and more.

A Flash Flood of Selling: Cramer's 'Mad Money' Recap (Thursday 4/19/18)

A Flash Flood of Selling: Cramer's 'Mad Money' Recap (Thursday 4/19/18)

Interest rates, inflation and bonds all add up, says Jim Cramer. And now, the trade war with China's getting ugly.

ACADIA Pharmaceuticals To Present At The 17th Annual Needham Healthcare Conference On March 27, 2018

ACADIA Pharmaceuticals To Present At The 17th Annual Needham Healthcare Conference On March 27, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

Acadia Pharmaceuticals Stock Sees Short Interest Move 10.7% Lower

Acadia Pharmaceuticals Stock Sees Short Interest Move 10.7% Lower

The most recent short interest data has been released for the 02/28/2018 settlement date, which shows a 1,239,260 share decrease in total short interest for Acadia Pharmaceuticals Inc , to 10,355,126, a decrease of 10.69% since 02/15/2018. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

TheStreet Quant Rating: D- (Sell)